PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
A new lung cancer niche is a major focus of Asco, with China's Dizal perhaps boasting the most intriguing dataset.
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
But how will the complex J&J bispecific antibody fare in a market where oral small molecules are the norm?
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.